Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Receives Average Recommendation of “Buy” from Brokerages

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) have received an average recommendation of “Buy” from the twelve ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $44.00.

Several research analysts recently weighed in on the company. TD Cowen upgraded Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, August 24th. Jefferies Financial Group started coverage on Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They issued a “buy” rating and a $50.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, July 21st. Wedbush raised their price target on Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Thursday, July 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, September 14th.

Damora Therapeutics, Inc. Common Stock Stock Down 0.8%

NASDAQ DMRA opened at $20.27 on Friday. Damora Therapeutics, Inc. Common Stock has a 52 week low of $3.50 and a 52 week high of $38.33. The company has a 50 day moving average price of $28.64 and a 200 day moving average price of $26.38. The firm has a market cap of $1.25 billion, a PE ratio of -6.01 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last announced its earnings results on Monday, August 10th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.06. On average, equities research analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current fiscal year.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

Several large investors have recently bought and sold shares of the stock. Braidwell LP acquired a new position in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at $42,146,000. Seven Fleet Capital Management LP acquired a new stake in Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth about $7,398,000. Squarepoint Ops LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth about $303,000. Finally, Arizona State Retirement System purchased a new stake in Damora Therapeutics, Inc. Common Stock during the 2nd quarter valued at about $260,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.